Verdinexor (KPT-335)

产品编号: DC8429
Verdinexor (KPT-335)
结构式
1392136-43-4
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.
Cas No.: 1392136-43-4
名称: (2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide
别名: KPT-335,KPT 335,KPT335
SMILES: O=C(NNC1=NC=CC=C1)/C=C\N1N=C(C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)N=C1
分子式: C18H12F6N6O
分子量: 442.32
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: Verdinexor inhibits the viability of Jurkat, OCI-Ly3, OCI-Ly10, and CLBL1 cells with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. KPT-335 also induces apoptosis in CLBL1 cells and primary canine DLBCL cells that express XPO1 and SINE. Verdinexor potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain. Verdinexor (25 mg/kg twice daily, p.o.) reduces proinflammatory cytokine expression in the lung, produces in vivo antiviral activity by reducing lung virus titers, and thus reduces pulmonary disease pathogenesis and death associated with lethal influenza A virus challenge. In autosomal-dominant polycystic kidney disease model, Verdinexor (5 mg/kg, i.p.) attenuates cyst growth via inhibition of XPO1. For the detailed information of Verdinexor (KPT-335), the solubility of Verdinexor (KPT-335) in water, the solubility of Verdinexor (KPT-335) in DMSO, the solubility of Verdinexor (KPT-335) in PBS buffer, the animal experiment (test) of Verdinexor (KPT-335), the cell expriment (test) of Verdinexor (KPT-335), the in vivo, in vitro and clinical trial test of Verdinexor (KPT-335), the EC50, IC50,and affinity,of Verdinexor (KPT-335), For the detailed information of Verdinexor (KPT-335), the solubility of Verdinexor (KPT-335) in water, the solubility of Verdinexor (KPT-335) in DMSO, the solubility of Verdinexor (KPT-335) in PBS buffer, the animal experiment (test) of Verdinexor (KPT-335), the cell expriment (test) of Verdinexor (KPT-335), the in vivo, in vitro and clinical trial test of Verdinexor (KPT-335), the EC50, IC50,and affinity,of Verdinexor (KPT-335), Please contact DC Chemicals.
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_3476_DC8429_1392136-43-4
COA
LOT NO. DOWNLOAD
产品编号 产品名称 应用领域
DC8429 Verdinexor (KPT-335) Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.